Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales by Product, Application & End-users The global digital biomarkers market will witness a robust CAGR of 35.7%, valued at $1.51 billion in 2021, expected to appreciate and reach $23.86 billion by 2030, confirms Strategic Market Research. Digital Biomarkers are the data used to track anatomical, psychological and behavioural changes in the human body using various sensors, Machine Learning (ML) and Artificial Intelligence (AI) techniques thereby making the data available to the wearer and other concerned users. The big data insights available in the healthcare industry are currently generated primarily by digital biomarkers. They assist in analysing the existing along with the predictable health conditions and/or adverse situations. The devices are present in form of wearables, portables, and digestible and implantable devices. The market has seen an increase in the demand for the same due to advancing technologies and direct consumer usage through devices such as smartphones, smartwatches and medical bracelets. Two of the most common features in consumer wearables are the heart rate monitor and oxygen saturation (SpO2) monitor, which are essential in tracking heart and lung biostatistics to identify and warn users of any adverse reactions. According to the CDC, cardiovascular disease is responsible for the death of more than 960,000 people each year. Due to the COVID-19 pandemic, there has been an uptick in sales of consumer devices. Fitbit saw an increase in users for its product every year since 2014 with an average growth of 37% over the years. Key Market Drivers - Increased Healthcare Expenditure, Government Investments, Increased Usage of Smartwatches and Smartphones There has been an increase in healthcare expenditure globally. According to the National Health Expenditure Accounts (NHEA), the spending grew by 9.7% in 2020, reaching USD 4.1 trillion or USD 12,530 per person in the US. As a percentage of GDP, health spending stood at 19.7% of the gross domestic product. As per Eurostat, the European Union spent 9.94% of the GDP on healthcare, or Euro 1.38 trillion. Thus, with an increase in healthcare expenditures, there would be an increase in the demand for digital biomarkers, which in turn will proliferate the industry growth. Moreover, there has been a sharp increase in the usage of smartphones, smartwatches and wearable digital technological devices like medical bracelets and fitness trackers. As per the recent findings, Apple has the highest share in the smartwatch segment, at 30.1%, followed by Samsung at 10.1%. The year-on-year sales of smartwatches have been on an upswing which is further increasing the market for digital biomarkers. Similarly, smartphones too, have seen a sharp rise in sales over the past few years, having various sensors such as accelerometers and motion sensors that help in keeping a track of an individual’s health. Additionally, drug development is becoming a heavy capital expenditure and time-consuming process. Thus, the increase in investments in digital biomarkers would be time and resource-efficient. Market Restraints The high cost associated with setting up a manufacturing unit and marketing for digital biomarkers can be considered a industry restraint. Digital Biomarkers Market Trends and Opportunities (Advancing technology and related investments, Increased awareness) With the rapid advancement in technologies, companies are developing more digital biomarkers, hence it is most likely to mature as an attractive investment segment in the future. As per a study conducted by Vasudevanet al (2022), despite the varied definitions of digital biomarkers, there is a consistency in defining them as per the BEST (Biomarkers, EndpointS and Other Tools) glossary and it is used by the FDA. With the increase in acceptance of the types of data and devices, more companies are investing to manufacture digital biomarkers. Imagine AI, an Israeli company has secured funding of USD 21 million in May 2022 to further develop its patented algorithms for cancer pathology. Hence, it can be seen as an attractive investment. There has been a significant rise in digital biomarkers used by consumers and institutions. As per a study conducted by Piguet al (2020) published in the Journal for Frailty and Aging, the WHO action plan calls for ‘ Integrated Care for Older People’, ICOPE which calls for use of modern technology by providing the opportunity to add continuous data flow for analysis and real-time interpretations to keep track of the fragile health conditions of the senior citizens. Additionally, the CDC has found that notifications for Atrial Fibrillation on a specific smartwatch were matching 84% with an actual ECG for patients, thereby reducing the mortality risk among individuals. Hence we see an increase in the use of smartwatches and other consumer wearables which monitor multiple physiological factors of the human body. Market Analysis Of Different Segments Covered in the Report Based on System Components Biosensors Wearables Smartphones and Smartwatches Implantables Mobile applications Injectables Based on Application Cardiovascular Sleep and Movement Disorder Pain Management Gastrointestinal Neurodegenerative Pulmonary Psychiatric Diabetic Based on End-User Pharmaceutical companies Providers Payers Biotechnological companies Regional Coverage Analysis North America Canada USA Mexico Rest of North America Europe Germany United Kingdom France Italy Spain Remaining Countries of Europe Asia-Pacific Region Australia China India Japan South Korea The Middle East and Africa GCC South Africa Rest of Middle East and Africa South America Argentina Brazil Rest of South America Segments Analysis & Insights Going by the segment of System components, the smartphones and smartwatches segment dominated the industry with a share of around 46.11%. The number of users in the US for wearable devices as of 2021 was 63.9 million, with Apple smartwatch being the most used wearable device. The usage of smartphones has led to a major shift in the market. As of 2021, there were more than 6.2 billion smartphone users globally. This, in turn, has led to the development and use of mobile fitness applications, such as Fitnes22 and Google Fit, which use the smartphone’s sensors to measure data such as the number of steps walked and calories burned. This increases the method by which a company can develop a digital biomarker with the assistance of the components of a smartphone. Given the wide variety of applications that are possible, there are many ways to further enhance the digital biomarkers market. The neurodegenerative segment currently holds the largest share of 19.41% and would continue to do so in the forecasted period. According to the National Institute of Environmental Health Sciences, as of 2021, Americans suffering from Alzheimer’s disease were estimated to be nearly 6.2 million people, followed by 1 million patients of Parkinson’s disease and nearly 400,000 multiple sclerosis (MS) patients. The second-largest industry share was for the devices monitoring cardiovascular health. The reason for this can be attributed to the rising usage of smart wearable devices which primarily monitor heart rate and also the increasing rate of cardiovascular diseases. According to the CDC, heart disease is the leading cause of death in the United States, with over 659,000 people dying each year. Given the numbers, there is scope to develop digital biomarkers aimed at cardiovascular disorders. In a study published in 2020 in the Nature Medicine Journal, by Avram et al using smartphones, a photoplethysmograph was used to develop a deep neural network to detect the various symptoms of diabetes prevalent in the individual. This also gave an immense scope for the companies to have R&D divisions dedicated to the development of digital biomarkers for more chronic diseases like asthma, cancer and arthritis. The market for voice-based digital biomarkers is also being developed by companies such as Sage Bionetworks. The primary end-users of this segment are biotechnological and pharmaceutical companies. The reason for their dominance can be attributed to acquisitions, mergers and investments into companies which are providing tools and solutions for the industry. For example, in September 2021, Merck partnered with Evidation Health to develop a program to monitor patients suffering from Alzheimer’s disease. Thus, the digital biomarkers market trend leads to various collaborations and mergers which further augment the market growth. By Region, the Asia Pacific region dominated the market with nearly 40.41% of the industry share. The high market share is attributed to the increased population and rising number of smart device users. According to the United Nations Population Fund, APAC accounts for nearly 60% of the global population (estimated at around 4.31 billion). The rise in diabetes patients is also driving the industry growth in this region. According to the International Diabetes Foundation, China and India have the highest rates of diabetes regionally and globally, with 116 million and 77 million patients with diabetes respectively as of 2019. Digital Biomarkers Market Report Coverage Report Attribute Details Forecast Period 2021-2030 Market size value in 2021 $1.51 Billion Revenue forecast in 2030 $23.56 Billion Growth rate 35.7% Base year for estimation 2021 Historical data 2017 - 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By System Components, By Application, By End-User and By Region Based on Components Biosensors,Wearables By Application Cardiovascular, Sleep and Movement Disorder By End-User Pharmaceutical companies,Providers,Payers,Biotechnological companie By Region U.S, Mexico, Canada and Rest of North America Country Scope U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc. Company Usability Profiles Abbott,AliveCor Inc,Alphabet, Inc,Bayer AG,Biogen, Inc,Evidation Health, Inc,Eli Lilly and Company,Fitbit, Inc,GlaxoSmithKline Plc,Happify Health,Medopad Ltd,Mindstrong Health,Novartis International AG,Pfizer Inc,Sanofi S.A,Verily Life Sciences Global Digital Biomarkers Market Competitive Landscape Analysis The industry globally involves with many firms, consisting of players from the pharmaceutical industry and various technological companies : Abbott AliveCor, Inc Alphabet, Inc Bayer AG Biogen, Inc Evidation Health, Inc Eli Lilly and Company Fitbit, Inc GlaxoSmithKline Plc Happify Health Medopad Ltd Mindstrong Health Novartis International AG Pfizer Inc Sanofi S.A Verily Life Sciences Recent developments In February 2022, a US-based digital biomarker company Koneksa announced that it received USD 45 million in funding for the expansion of its scientific team and clinical platform. In May 2022, an Israeli start-up NeuraLight, raised USD 25 million in funding to develop a program that uses deep learning and computer vision to determine if a person is suffering from a neurological condition. The company aims to further develop its proprietary algorithms to diagnose complicated neurological conditions like ALS and Parkinson’s disease. In May 2022, a Northern Ireland company called Cumulus Neuroscience began a set of clinical trials to further evaluate the efficiency of their toolkit to track the course of neurodegenerative diseases. Currently, there are devices and methodologies present for the same, however, Cumulus aims at improving the efficiency for better output. In June 2022, Korean Medical AI Company, VUNO, announced the results of its study on digital biomarkers and their impact on detecting liver cancer. This specific AI-driven digital pathology examination targets liver cancer and confirmed image-based digital biomarkers. It is executed by the digital pathology data coupled with analysis of genomes and clinical records. In May 2022, American neuroscience company Altoida joined a project of the Digital Medicine Society’s (DiMe) -the Alzheimer’s Disease and Related Dementia Digital Measures Development Project. The project is a collaboration of multiple companies that are involved in developing neuroscientific digital biomarkers. In April 2022, Mitsubishi Tanabe Pharma America (MTHA) joined the consortium of EverythingALS, an American non-profit working to bring technology and data with solutions to the medical field. The collaboration of the companies is aimed at further developing the tools for digital biomarkers in the field of amyotrophic lateral sclerosis (ALS). Various Digital Biomarker Commercial Products Being Manufactured by Leaders of the Market Name Feature Key Player FreeStyleLibre Sensor-based glucose monitoring system is used to measure glucose levels every minute Abbott FitBit Charge 5 Used for Patented ECG, ElectroDermal Activity (EDA) Scan, SpO2 Measurement, and Skin Temperature Tracking Fitbit DeepMass Machine Learning tool that uses mass spectrometry to identify proteins that cause diseases Verily Life Sciences Frequently Asked Question About This Report What would be the impact on digital biomarkers in the Asia Pacific region? Digital biomarkers would significantly increase the ability of clinicians to diagnose and treat diseases better What is the digital biomarkers market growth? The global digital biomarkers market is expected to grow at a compound annual growth rate (CAGR) of 35.17% from 2021 to 2030 to reach $23.56 Billion by 2030. Which factors are driving the growth of the market? Advancing technology and investments in the sector as well the rising use of smart devices by the vast majority of the global population. How big is the digital biomarkers market? The global digital biomarkers market size was $1.51 Billion in 2021 and is predicted to reach $23.56 Billion by 2030 with a CAGR of 35.17%. What will be the value of the market in 2030? The value of the market share in 2030 will be around USD 23.31 billion Sources https://www.cdc.gov/heartdisease/facts.htm https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12328 https://www.cdc.gov/heartdisease/facts.htm https://www.un.org/en/global-issues/population https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at Market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Digital Biomarker Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Digital Biomarker Market 4.2.1 Market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 Market, by Region, 2021-2030 (USD Million) 4.4 By System Components Business Analysis 4.4.1 Market, By System Components, 2021-2030 (USD Million) 4.5 By End-User Business Analysis 4.5.1 Market, By End-User, 2021-2030 (USD Million) 4.6 Application Business Analysis 4.6.1 Market, By Application, 2021-2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9Business Environment Analysis Tool 4.9.1 Market PEST analysis 4.9.2 Market Porter’s analysis 4.10Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Application Analysis 5.11.1. Trends in Application (2014-2020) 5.11.2. Trends in Application (2021-2030) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product Payload 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By System Components Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Biosensors 7.3.1. Biosensors, 2021-2030 (USD Million) 7.4. Wearables 7.4.1. Wearables Market, 2021-2030 (USD Million) 7.5. Smartphones and Smartwatches 7.5.1. Smartphones and Smartwatches Market, 2021-2030 (USD Million) 7.6. Implantables 7.6.1. Implantables Market, 2021-2030 (USD Million) 7.7. Mobile applications 7.7.1. Mobile applications Market, 2021-2030 (USD Million) 7.8. Ingestables 7.8.1. Ingestables Market, 2021-2030 (USD Million) 8. Market: By End-User Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Pharmaceutical companies 8.3.1. Pharmaceutical companies Market, 2021-2030 (USD Million) 8.4. Providers 8.4.1. Providers Market, 2021-2030 (USD Million) 8.5. Payers 8.5.1. Payers Market, 2021-2030 (USD Million) 8.6. Biotechnological companies 8.6.1. Biotechnological companies Market, 2021-2030 (USD Million) 9. Market: By Application Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Cardiovascular 9.3.1. Cardiovascular Market, 2021-2030 (USD Million) 9.4. Sleep and Movement Disorder 9.4.1. Sleep and Movement Disorder Market, 2021-2030 (USD Million) 9.5. Pain Management 9.5.1. Pain Management Market, 2021-2030 (USD Million) 9.6. Gastrointestinal 9.6.1. Gastrointestinal Market, 2021-2030 (USD Million) 9.7. Neurodegenerative 9.7.1. Neurodegenerative Market, 2021-2030 (USD Million) 9.8. Pulmonary 9.8.1. Pulmonary Market, 2021-2030 (USD Million) 9.9. Psychiatric 9.9.1. Psychiatric Market, 2021-2030 (USD Million) 9.10. Diabetic 9.10.1. Diabetic Market, 2021-2030 (USD Million) 10. Market: Regional Outlook 10.1 North America 10.1.1. North America Market, by By System Components, 2021-2030 (USD Million) 10.1.2. North America Market, by By End-User, 2021-2030 (USD Million) 10.1.3. North America Market, by Application, 2021-2030 (USD Million) 10.1.4. North America Market, by Country, 2021-2030 (USD Million) 10.1.4.1. U.S. 10.1.4.1.1. U.S. Market, by By System Components, 2021-2030 (USD Million) 10.1.4.1.2. U.S. Market, by By End-User, 2021-2030 (USD Million) 10.1.4.1.3. U.S. Market, by Application, 2021-2030 (USD Million) 10.1.4.2.Canada 10.1.4.2.1. Canada Market, by By System Components, 2021-2030 (USD Million) 10.1.4.2.2. Canada Market, by By End-User, 2021-2030 (USD Million) 10.1.4.2.3. Canada Market, by Application, 2021-2030 (USD Million) 10.2. Europe 10.2.1. Europe Market, by By System Components, 2021-2030 (USD Million) 10.2.2. Europe Market, by By End-User, 2021-2030 (USD Million) 10.2.3. Europe Market, by Application, 2021-2030 (USD Million) 10.2.4. Europe Market, by country, 2021-2030 (USD Million) 10.2.4.1 U.K. 10.2.4.1.1. U.K. Market, by By System Components, 2021-2030 (USD Million) 10.2.4.1.2. U.K. Market, by By End-User, 2021-2030 (USD Million) 10.2.4.1.3. U.K. Market, by Application, 2021-2030 (USD Million) 10.2.4.2. Germany 10.2.4.2.1. Germany Market, by By System Components, 2021-2030 (USD Million) 10.2.4.2.2. Germany Market, by By End-User, 2021-2030 (USD Million) 10.2.4.2.3. Germany Market, by Application, 2021-2030 (USD Million) 10.2.4.3. France 10.2.4.3.1. France Market, by By System Components, 2021-2030 (USD Million) 10.2.4.3.2. France Market, by By End-User, 2021-2030 (USD Million) 10.2.4.3.3. France Market, by Application, 2021-2030 (USD Million) 10.2.4.4. Rest of Europe 10.2.4.4.1. Rest of Europe Market, by By System Components, 2021-2030 (USD Million) 10.2.4.4.2. Rest of Europe Market, by By End-User, 2021-2030 (USD Million) 10.2.4.4.3. Rest of Europe Market, by Application, 2021-2030 (USD Million) 10.3. Asia Pacific 10.3.1. Asia Pacific Market, by By System Components, 2021-2030 (USD Million) 10.3.2. Asia Pacific Market, by By End-User, 2021-2030 (USD Million) 10.3.3. Asia Pacific Market, by Application, 2021-2030 (USD Million) 10.3.4. Asia Pacific Market, by country, 2021-2030 (USD Million) 10.3.4.1. China 10.3.4.1.1. China Market, by By System Components, 2021-2030 (USD Million) 10.3.4.1.2. China Market, by By End-User, 2021-2030 (USD Million) 10.3.4.1.3. China Market, by Application, 2021-2030 (USD Million) 10.3.4.2. India 10.3.4.2.1. India Market, by By System Components, 2021-2030 (USD Million) 10.3.4.2.2. India Market, by By End-User, 2021-2030 (USD Million) 10.3.4.2.3. India Market, by Application, 2021-2030 (USD Million) 10.3.4.3. Japan 10.3.4.3.1. Japan Market, by By System Components, 2021-2030 (USD Million) 10.3.4.3.2. Japan Market, by By End-User, 2021-2030 (USD Million) 10.3.4.3.3. Japan Market, by Application, 2021-2030 (USD Million) 10.3.4.4. South Korea 10.3.4.4.1. South Korea Market, by By System Components, 2021-2030 (USD Million) 10.3.4.4.2. South Korea Market, by By End-User, 2021-2030 (USD Million) 10.3.4.4.3. South Korea Market, by Application, 2021-2030 (USD Million) 10.3.4.5. Rest of ASIA PACIFIC 10.3.4.5.1. Rest of ASIA PACIFIC Market, by By System Components, 2021-2030 (USD Million) 10.3.4.5.2. Rest of ASIA PACIFIC Market, by By End-User, 2021-2030 (USD Million) 10.3.4.5.3. Rest of ASIA PACIFIC Market, by Application, 2021-2030 (USD Million) 10.4. Latin America 10.4.1. Latin America Market, by By System Components, 2021-2030 (USD Million) 10.4.2. Latin America Market, by By End-User, 2021-2030 (USD Million) 10.4.3. Latin America Market, by Application, 2021-2030 (USD Million) 10.4.4. Latin America Market, by country, 2021-2030 (USD Million) 10.4.4.1. Brazil 10.4.4.1.1. Brazil Market, by By System Components, 2021-2030 (USD Million) 10.4.4.1.2. Brazil Market, by By End-User, 2021-2030 (USD Million) 10.4.4.1.3. Brazil Market, by Application, 2021-2030 (USD Million) 10.4.4.2. Mexico 10.4.4.2.1. Mexico Market, by By System Components, 2021-2030 (USD Million) 10.4.4.2.2. Mexico Market, by By End-User, 2021-2030 (USD Million) 10.4.4.2.3. Mexico Market, by Application, 2021-2030 (USD Million) 10.4.4.3. Rest of the Latin America 10.4.4.3.1. Rest of the Latin America Market, by By System Components, 2021-2030 (USD Million) 10.4.4.3.2. Rest of the Latin America Market, by By End-User, 2021-2030 (USD Million) 10.4.4.3.3. Rest of the Latin America Market, by Application, 2021-2030 (USD Million) 10.5. MEA 10.5.1. MEA Market, by By System Components, 2021-2030 (USD Million) 10.5.2. MEA Market, by By End-User, 2021-2030 (USD Million) 10.5.3. MEA Market, by Application, 2021-2030 (USD Million) 10.5.4. MEA Market, by Region, 2021-2030 (USD Million) 11. Competitive Landscape 11.1 Bayer AGott 11.1.1. Company overview 11.1.2. Financial performance 11.1.3. ProductPortfolio Analysis 11.1.4. Business Strategy & Recent Development 11.2. ALIVECOR, INC 11.2.1. Company overview 11.2.2. Financial performance 11.2.3. Product Portfolio Analysis 11.2.4. Business Strategy & Recent Development 11.3. ALPHABET, INC 11.3.1. Company overview 11.3.2. Financial performance 11.3.3. Product Portfolio Analysis 11.3.4. Business Strategy & Recent Development 11.4. BAYER AG 11.4.1. Company overview 11.4.2. Financial performance 11.4.3. Product Portfolio Analysis 11.4.4. Business Strategy & Recent Development 11.5. BIOGEN, INC 11.5.1. Company overview 11.5.2. Financial performance 11.5.3. Product Portfolio Analysis 11.5.4. Business Strategy & Recent Development 11.6. Evidation Health, Inc 11.6.1. Company overview 11.6.2. Financial performance 11.6.3. Product Portfolio Analysis 11.6.4. Business Strategy & Recent Development 11.7. Eli Lilly and Company 11.7.1. Company overview 11.7.2. Financial performance 11.7.3. Product Portfolio Analysis 11.7.4. Business Strategy & Recent Development 11.8. Fitbit, Inc 11.8.1. Company overview 11.8.2. Financial performance 11.8.3. Product Portfolio Analysis 11.8.4. Business Strategy & Recent Development 11.9. GlaxoSmithKline Plc 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.10. Happify Health 11.10.1. Company overview 11.10.2. Financial performance 11.10.3. Product Portfolio Analysis 11.10.4. Business Strategy & Recent Development 11.11. Medopad Ltd 11.11.1. Company overview 11.11.2. Financial performance 11.11.3. Product Portfolio Analysis 11.11.4. Business Strategy & Recent Development 11.12. Mindstrong Health 11.12.1. Company overview 11.12.2. Financial performance 11.12.3. Product Portfolio Analysis 11.12.4. Business Strategy & Recent Development 11.13. Novartis International AG 11.13.1. Company overview 11.13.2. Financial performance 11.13.3. Product Portfolio Analysis 11.13.4. Business Strategy & Recent Development 11.14. Pfizer Inc 11.14.1. Company overview 11.14.2. Financial performance 11.14.3. Product Portfolio Analysis 11.14.4. Business Strategy & Recent Development 11.15. Sanofi S.A 11.15.1. Company overview 11.15.2. Financial performance 11.15.3. Product Portfolio Analysis 11.15.4. Business Strategy & Recent Development 11.15. Verily Life Sciences 11.15.1. Company overview 11.15.2. Financial performance 11.15.3. Product Portfolio Analysis 11.15.4. Business Strategy & Recent Development List of Tables (66 Tables) TABLE 1. Market, By System Components, 2021-2030 (USD Million) TABLE 2. Market FOR Biosensors, BY REGION, 2021-2030 (USD Million) TABLE 3. Market FOR Wearables, BY REGION, 2021-2030 (USD Million) TABLE 4. Market FOR Smartphones and Smartwatches, BY REGION, 2021-2030 (USD Million) TABLE 5. Market, By End-User, 2021-2030 (USD Million) TABLE 6. Market FOR Pharmaceutical companies, BY REGION, 2021-2030 (USD Million) TABLE 7. Market FOR Providers, BY REGION, 2021-2030 (USD Million) TABLE 8. Market FOR Payers, BY REGION, 2021-2030 (USD Million) TABLE 9. Market FOR Biotechnological companies, BY REGION, 2021-2030 (USD Million) TABLE 10. Market FOR Neurodegenerative, BY REGION, 2021-2030 (USD Million) TABLE 11. Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 12. Market FOR Cardiovascular, BY REGION, 2021-2030 (USD Million) TABLE 13. Market FOR Sleep and Movement Disorder, BY REGION, 2021-2030 (USD Million) TABLE 14. Market FOR Pain Management, BY REGION, 2021-2030 (USD Million) TABLE 15. Market FOR Gastrointestinal, BY REGION, 2021-2030 (USD Million) TABLE 16. Market FOR Neurodegenerative, BY REGION, 2021-2030 (USD Million) TABLE 17. Market FOR Battery Powered , BY REGION, 2021-2030 (USD Million) TABLE 18. Market, BY REGION, 2021-2030 (USD Million) TABLE 19. NORTH AMERICA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 20. NORTH AMERICA Market, By System Components, 2021-2030 (USD Million) TABLE 21. NORTH AMERICA Market, By End-User, 2021-2030 (USD Million) TABLE 22. NORTH AMERICA Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 23. EUROPE Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 24. EUROPE Market, By System Components, 2021-2030 (USD Million) TABLE 25. EUROPE Market, By End-User, 2021-2030 (USD Million) TABLE 26. EUROPE Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 27. ASIA-PACIFIC Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 28. ASIA-PACIFIC Market, By System Components, 2021-2030 (USD Million) TABLE 29. ASIA-PACIFIC Market, By End-User, 2021-2030 (USD Million) TABLE 30. ASIA-PACIFIC Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 31. LAMEA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 32. LAMEA Market, By System Components, 2021-2030 (USD Million) TABLE 33. LAMEA Market, By End-User, 2021-2030 (USD Million) TABLE 34. LAMEA Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 35. Bayer AGott: COMPANY SNAPSHOT TABLE 36. Bayer AGott: OPERATING SEGMENTS TABLE 37. ALIVECOR, INC: COMPANY SNAPSHOT TABLE 38. ALIVECOR, INC: OPERATING SEGMENTS TABLE 39. ALPHABET, INC: COMPANY SNAPSHOT TABLE 40. ALPHABET, INC: OPERATING SEGMENTS TABLE 41. BAYER AG : COMPANY SNAPSHOT TABLE 42. BAYER AG : OPERATING SEGMENTS TABLE 43. BIOGEN, INC: COMPANY SNAPSHOT TABLE 44. BIOGEN, INC: OPERATING SEGMENTS TABLE 45. Evidation Health, Inc: COMPANY SNAPSHOT TABLE 46. Evidation Health, Inc: OPERATING SEGMENTS TABLE 47. Eli Lilly and Company: COMPANY SNAPSHOT TABLE 48. Eli Lilly and Company: OPERATING SEGMENTS TABLE 49. Doosan Robotics: COMPANY SNAPSHOT TABLE 50. Doosan Robotics: OPERATING SEGMENTS TABLE 51. GlaxoSmithKline Plc: COMPANY SNAPSHOT TABLE 52. GlaxoSmithKline Plc: OPERATING SEGMENTS TABLE 53. Happify Health: COMPANY SNAPSHOT TABLE 54. Happify Health: OPERATING SEGMENTS TABLE 55. Medopad Ltd: COMPANY SNAPSHOT TABLE 56. Medopad Ltd: OPERATING SEGMENTS TABLE 57. Denso Corporation: COMPANY SNAPSHOT TABLE 58. Denso Corporation: OPERATING SEGMENTS TABLE 59. Novartis International AG: COMPANY SNAPSHOT TABLE 60. Novartis International AG: OPERATING SEGMENTS TABLE 61. Pfizer Inc: COMPANY SNAPSHOT TABLE 62. Pfizer Inc: OPERATING SEGMENTS TABLE 63. Sanofi S.A: COMPANY SNAPSHOT TABLE 64. Sanofi S.A: OPERATING SEGMENTS TABLE 65. Verily Life Sciences: COMPANY SNAPSHOT TABLE 66. Verily Life Sciences: OPERATING SEGMENTS List of Figures (22 Figures) Figure 1 Digital Biomarker Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 15 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Digital Biomarker, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Digital Biomarker, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By End-User, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By Application, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By System Components, 2019 vs. 2025 (USD Million) Figure 14 Geographical Snapshot of the Market Figure 15 upto 5kgto Witness Higher CAGR in Market for Payload Segment during Forecast Period. Figure 16Sleep and Movement Disorder to Witness Higher CAGR in Market for Application Segment during Forecast Period. Figure 17Pharmaceutical companies to Witness Higher CAGR in the Market for End-User Segment during Forecast Period. Figure 18APAC Region Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges Figure 20 North America: Market Snapshot Figure 21 Asia Pacific: Market Snapshot Figure 22 Vendor Dive: Evaluation Overview